Form 8-K TREVENA INC For: Mar 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Trevena (TRVN) says FDA informed it that data were not sufficient to support continuation of previously granted Breakthrough Therapy designation for oliceridine
March 7, 2019 4:32 PM ESTTrevena (NASDAQ: TRVN) disclosed in an SEC filing:
In February 2016, based on the preliminary evidence from Trevenas (the Company) Phase 2 clinical studies of oliceridine, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to oliceridine for the management of moderate to severe acute pain. Breakthrough Therapy designation is granted by the FDA to new therapies intended to treat serious or life-threatening conditions and for which preliminary... More
